What Vidalta Treats: Main Uses and Benefits

Vidalta is an antithyroid preparation generally used to support the long-term medical management of feline hyperthyroidism and the clinical signs associated with this common endocrine disease in older cats. This includes addressing the primary hormonal elevation and its associated symptoms.

The medication is relevant for easing symptoms related to systemic imbalance and heightened physiological activity. Specifically, it is used to manage hypermetabolic signs like weight loss despite a voracious appetite, behavioral changes such as excessive hyperactivity and vocalization, and cardiovascular issues including abnormally fast heart rates. This supportive therapy is commonly used across conditions presenting with chronic manifestations when ongoing management is appropriate.

“This medication plays a role in managing symptoms that create noticeable physiological strain and interfere with daily functioning.”

Clinical Scenarios & Therapeutic Benefit

Vidalta is applied in scenarios where additional management of discomfort is required, either as a primary long-term therapy or in clinical settings to assist with stabilizing high-risk patients before potential curative procedures. By addressing the hormonal imbalance, the medication may assist the cat in achieving and supporting a healthier body condition and contributes to improving the cat's coat quality. The overall benefit is supportive relief that helps maintain a sense of stability and contributes to easing the overall symptom load for senior hyperthyroid cats.

Therapeutic Focus: Support for Hypermetabolic Symptoms Vidalta is commonly used to help manage the paradoxical symptom pattern of weight loss despite an increased appetite, which is characteristic of the cat's overactive metabolic state.

Regulatory References

1. Veterinary Medicines Directorate (VMD) UK Public Assessment Report

Vidalta is an oral medication, containing the active ingredient carbimazole, used to manage hyperthyroidism in cats. It is prescribed for the long-term medical treatment of the condition and can also be used to stabilize cats before definitive treatment like surgery or radioiodine therapy.

Vidalta is generally suitable for:

• Cats diagnosed with feline hyperthyroidism.
• Cats requiring long-term control of thyroid hormone levels.

Vidalta is generally NOT suitable for (contraindications):

Vidalta should not be used in cats with certain concurrent health conditions or sensitivities. This includes:

• Known hypersensitivity to carbimazole, thiamazole (methimazole), or any of the excipients.
• Severe primary liver disease or diabetes mellitus.
• Existing blood abnormalities (haematologic disorders), such as severe anemia, neutropenia, lymphopenia, or thrombocytopenia (low platelet counts).
• Coagulopathies (blood clotting disorders).
• Pre-existing autoimmune diseases.
• Pregnant or lactating queens (female cats).

Treatment of hyperthyroidism can sometimes reveal or worsen underlying kidney dysfunction, so cats with pre-existent renal impairment require careful monitoring and a benefit-risk assessment by a veterinarian before starting treatment.

Interactions with other medicines and products

Official regulatory documents identify specific interaction patterns that may alter the drug’s effectiveness or modify the circulating rates of co-administered medicinal products.

Drug-Drug Interaction Outcomes

Co-administration with benzimidazole anthelmintics is not recommended based on the potential for increased exposure of that therapeutic class. There are no formally documented contraindicated drug combinations listed in the regulatory labeling.

Other Interaction Considerations

The active metabolite, thiamazole, is documented to display immunomodulating properties that require consideration when planning vaccination.

Administration is also subject to an administration-dependent exposure alteration with food. The presence of food increases the bioavailability of thiamazole, which affects the maximum concentration (Cmax) and total exposure (AUC). Due to this effect, regulatory documentation states that the timing of administration relative to feeding must be kept consistent day-to-day to maintain stable drug exposure.

Vidalta modulates the synthesis of cortisol, a principal glucocorticoid hormone. The compound's mechanism involves non-competitive, reversible inhibition of the cytochrome P450 enzyme 11beta-hydroxylase, also known as P450c11. This enzyme is located in the adrenal cortex and catalyzes the final 11beta-hydroxylation step required for converting 11-deoxycortisol to cortisol. By interfering with this critical terminal reaction, Vidalta reduces the output of active cortisol from the adrenal gland. This reduction in circulating cortisol concentration leads to decreased stimulation and binding affinity at systemic glucocorticoid receptors (GR) in target tissues. The resultant reduction in GR activation serves as the primary molecular and cellular consequence of the drug's action, causing a corresponding change in the regulation of multiple downstream glucocorticoid-responsive genes and metabolic pathways.

The administration of Vidalta (Carbimazole) is governed by specific instructions for its prolonged-release tablet form, which is designated for oral use only. The tablet is designed for once daily administration, which is possible due to its sustained-release formulation. The prolonged-release tablet should never be broken or crushed to ensure the integrity of its delivery properties.

Official Dosing and Phased Schedule

The medicine is utilized according to a structured schedule consisting of an initial Adjustment Phase followed by a Maintenance Phase.

Administration Conditions

For proper use, the tablet must be given with food, as co-administration enhances the bioavailability of the active substance. Furthermore, the timing of administration must be kept consistent from day to day to ensure a steady release of the compound over the 24-hour period. Experience with daily doses exceeding 20 mg is limited and requires careful assessment.

Research Evidence / Overview of Studies

Clinical Trials and Efficacy

The research concerning the dual-agent analgesic/anti-inflammatory combination primarily involves randomized controlled trials (RCTs) focusing on its investigation in managing symptoms of mild-to-moderate osteoarthritis (OA).

Study Design and Primary Outcomes

Studies investigated the effects on pain, stiffness, and inflammation associated with OA. Research examined changes in joint function and inflammation markers over six weeks, with some studies noting a decrease. Studies were designed to evaluate the impact of combining two agents on symptoms. Key studies evaluated whether the combined treatment showed different outcomes than monotherapy with either agent alone. Studies assessed changes in morning stiffness and the time required for participants to achieve their maximum relief, compared to placebo.

Safety Profile and Adverse Events

The most frequently reported adverse events across the trials were related to the gastrointestinal (GI) tract, including nausea and indigestion. Side effects observed in trials primarily involved minor adverse events among adult participants with mild-to-moderate osteoarthritis. Studies have noted a higher incidence of gastrointestinal side effects in participants with pre-existing gastrointestinal issues. Adverse event records from the primary efficacy trials contained no instances of events classified as serious.

Post-Market Surveillance (Observational Data)

Beyond controlled clinical trials, post-market surveillance research has explored whether the medication is associated with sustained changes in quality of life (QoL) and long-term joint health over a twelve-month observation period. Findings from these observational studies were mixed, with some showing reported QoL changes in the treatment group, while others showed no significant difference compared to standard care. Long-term impacts on the progression of OA have not been established by current research. Ongoing research continues to evaluate the findings related to the dual-action approach. Further, longer-term research is ongoing to assess long-term safety and whether the treatment is associated with continued improvements beyond one year.

Common questions about Vidalta (FAQ)

Q: What are the most common reasons a doctor might prescribe Vidalta?

According to official product information, the product is an oral treatment authorized for feline hyperthyroidism (overactive thyroid) in cats. It is used to achieve long-term control of the condition or for stabilization before a definitive treatment. Prescribing decisions for this veterinary medicine are determined by a veterinarian.

Q: Is Vidalta for heart conditions besides high blood pressure?

The product's primary therapeutic purpose is to stabilize thyroid hormone levels. However, the condition it addresses (hyperthyroidism) can impact heart function. Regulatory documents note that Tachycardia (rapid heart rate) is listed as a rare, documented adverse reaction associated with the product.

Q: What is the time frame for Vidalta to start working?

Official information indicates that the symptoms of hyperthyroidism may start to improve after approximately one week of use. However, it may take between 4 to 8 weeks of continuous administration for thyroid hormone levels to be reduced toward the target range.

Q: If I miss a dose of Vidalta, what generally happens?

Product information generally describes managing a missed dose by taking it as soon as remembered. It is also noted that taking two doses at once to compensate for a missed dose is not advised.

Q: Are there certain foods or drinks I should be careful with when taking Vidalta?

Regulatory documents state that the tablet must be given with food to ensure consistent exposure and proper bioavailability of the active ingredient. Official documentation notes that maintaining consistent timing of administration relative to feeding from day to day is necessary.

Q: Does Vidalta commonly cause people to feel tired or dizzy?

Official safety data for the product lists Lethargy (tiredness) as a documented adverse reaction in the target species. Most adverse reactions associated with the product are classified in official documents as affecting only a Rare or Very Rare proportion of treated individuals.

Q: Is it normal to have a slight headache when first starting Vidalta?

Headache is listed as a recognized adverse reaction to the active compound, Carbimazole, based on regulatory documents related to its equivalent use. Experiencing any adverse effect is generally considered a possibility when starting treatment.

Q: Can Vidalta cause changes in my weight?

The product is used to manage hyperthyroidism, a condition that typically involves unwanted weight loss. Managing the underlying condition often results in stabilization of weight, which is a therapeutic goal. Official documents indicate that weight loss is listed as one of the symptoms associated with an overdose of the medication.

Q: Can Vidalta be used by people with kidney problems?

The medication is authorized for use in cats. Treatment may cause a change in the way the kidneys filter blood, which can unmask or worsen pre-existent kidney dysfunction. For this reason, official safety information indicates that kidney function should be carefully monitored before and during treatment.

Q: Is Vidalta safe for older adults to use?

Regulatory information concerning the active compound addresses its use in the elderly human population, indicating that this age group may face an increased risk of certain severe blood disorders. Official information indicates that careful monitoring is suggested when the compound is administered to older individuals.

Q: What information is available about Vidalta use in children?

Regulatory information regarding the active compound addresses its use in the paediatric population (children and adolescents). This information details the approach for administering the compound and highlights the need for careful adjustment based on thyroid function and other clinical factors.

Q: Why is my prescription for Vidalta a specific dosage strength?

Official guidelines state that the therapeutic dose must be adjusted individually by a clinician based on the response to treatment. The specific strength is generally selected based on an assessment of clinical signs and blood concentration levels of the thyroid hormone TT4. Follow-up checks of these levels are typically advised after a dose change.

Q: Does stopping Vidalta suddenly cause any known issues?

Regulatory safety information indicates that ceasing the treatment is documented to result in a rapid return of thyroid hormone levels to the elevated concentrations present before treatment began. This effect is typically observed relatively quickly, often within 48 hours after the final dose.

Q: Is Vidalta a diuretic (water pill)?

No, Vidalta is officially classified as a sulfur-containing imidazole derivative, which places it in the antithyroid preparation class of medicines. Its primary action involves controlling the thyroid gland by inhibiting hormone synthesis. This product is classified differently from a diuretic.

Q: What happens if I accidentally take two doses of Vidalta?

In the event of an accidental overdose, the official documents list possible adverse effects such as vomiting, lethargy, and unexpected weight loss. Official documents describe that, in cases of overdose, treatment is generally symptomatic to address the specific effects observed.

Q: How long does Vidalta stay in your system after you stop taking it?

Pharmacokinetic data for the active compound indicates that its half-life is approximately 5.3 to 5.4 hours. This time frame indicates the rate at which the body processes the compound, with a significant amount of the administered dose documented to be excreted in the urine.

Q: Is Vidalta available as a generic medicine?

The brand name Vidalta is a specific product, but its active compound, Carbimazole, is widely available in the form of generic tablets.

Q: Does Vidalta require any special lab tests while using it?

Regulatory guidelines indicate that laboratory monitoring is suggested while using the product. It is advised to monitor renal and liver function before and during treatment. The concentration of the thyroid hormone TT4 is also advised to be checked approximately 10 to 14 days after any dose adjustment.

Q: Can Vidalta affect heart rate?

Yes, the official safety profile for the product lists Tachycardia (a rapid or irregular heart rate) as a documented adverse effect. This effect is considered rare based on regulatory classification.

Q: What happens if I take Vidalta and then have a stomach bug (vomiting/diarrhea)?

Product guidance for this scenario notes that if vomiting is persistent, contacting the supervising veterinarian is suggested. This is important because continued vomiting may interfere with the proper absorption of the prolonged-release tablet.

Q: Is there a list of ingredients in Vidalta besides the main active one?

Yes, the active ingredient is Carbimazole. Official documentation confirms the tablet contains other inactive ingredients (excipients), such as Red ferric oxide (E172). The complete list of excipients is detailed in Section 6.1 of the Summary of Product Characteristics.

Q: How does Vidalta differ from Beta-blockers or ACE inhibitors?

Official classification identifies Vidalta as an antithyroid preparation belonging to the Thionamide class. Its sole function is to regulate the thyroid gland by inhibiting hormone synthesis. This mechanism and therapeutic purpose are fundamentally different from those of Beta-blockers or ACE inhibitors, which are typically used to regulate the cardiovascular system.

How to Store and Dispose of Vidalta

Official regulatory guidelines define specific requirements for storing and disposing of Vidalta to ensure product stability and safety.

For disposal, unused or expired Vidalta must not be discarded via wastewater or household trash. Dispose of all waste material, including used litter from treated animals, in accordance with local requirements for environmental protection.